Disruptive Discoveries Journal by Chris Berry

Despite their small size (in terms of yearly production) relative to base metals or fertilizers, many of the Energy Metals which I follow continue to make their strategic significance felt. We have talked a great deal in recent months about global excesses in labor and capital putting a “lid” on commodity demand. A confluence of geopolitical and economic issues has come to the fore which has, I think, strengthened this thesis but has also paradoxically helped Energy Metals reassert their significance in global supply chains.

When it Happens…It’ll Happen Fast

The phrase above was said to me once by a money manager commenting on one of the main questions we have been asking ourselves in recent months. Namely, “When will this cycle turn?” With respect to Energy Metals, we could very well be at that tipping point.

[ Read The Whole Blog Post ]

By: Rachel Fox - FoxOnStocks.com

Apple’s new iPhone 6 is less than ONE month away from its debut on September 9th.

If the release is successful and people are receptive to the long awaited, new and improved iPhone, amazing things are said to happen for Apple and its stock price.

Apple’s earnings guidance according to analysts (predicted earnings for the next earnings quarter) will depend heavily on how high the sales numbers are for this new release.

I’m personally beyond excited to get my hands on it. I’ve been the proud owner of an iPhone since April of 2011 and don’t foresee using any other type of phone in the near future… or the distant future.

[ Read the Whole Blog Post ]

Amid growing frenzy over an Ebola outbreak in West Africa and fears it could spread, Canadian-based Tekmira Pharmaceuticals Corp.  has moved a little closer to getting approval for a treatment that combats the deadly virus, sending its shares soaring Friday.

Both U.S. and Canadian shares of Tekmira  TKMR +34.62%   CA:TKM +32.86% were up more than 28% in recent action, reaching new highs for the session.

Tekmira announced late Thursday that the U.S. Food and Drug Administration gave verbal approval to change the status on its drug, known as TKM-Ebola, to a partial clinical hold from a full clinical hold. The company says this could potentially allow the use of the drug in those already infected with Ebola. TKM-Ebola is being developed under a New Drug Application with the assistance of the Pentagon’s medical countermeasures office.

[ Read Whole Article ]

By Christopher Kuretich

NEW YORK (TheStreet) -- How many investors do you personally know? Chances are, half of the people you talk to do not have a clue what the stock market is or think of it as some super risky venture. The majority of the rest of the people have tried to invest or know someone who has, and lost some money. They give up and quit trying to make money from that route.

It is a shame, because the stock market has a proven history of being a very reliable way to build the wealth many people desire, to reach their specific goals. Losing money happens in the stock market and there is no need to quit because of it. Just like anything in life, you have to practice and learn from your mistakes to become a better investor. Not everyone is a winner; otherwise, there is not much of a reward if everyone can automatically become a winner.

[ Read The Whole Article ]

Goldman Sachs Group Inc.GS +0.64% says it knows what’s going to happen when the Federal Reserve starts raising interest rates.

The quick takeaway: Stocks look much more attractive than bonds–at least through 2018.

“We forecast a dramatic divergence between stock and bond returns during the next several years,” a Goldman team led by stock strategist David Kostin wrote to clients this week. Goldman predicts the S&P 500 will generate a 6% annualized total return between now and 2018, compared to a 1% annualized gain for the benchmark 10-year Treasury note, assuming the Fed starts raising rates in the middle of next year.

[ Read The Whole Article ]